The proteomic toolbox for studying cerebrospinal fluid

Expert Review of Proteomics

Volumn 9, Issue 2, 2012, Pages 165-179

  Van Gool, Alain J ^a,b,c,d   Hendrickson, Ronald C ^a,e  

^a MERCK RESEARCH LABORATORIES   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^d TNO   (Netherlands)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

biomarkers; CSF; drug development; proteomics; translational medicine

Indexed keywords

BIOLOGICAL MARKER;

BLOOD BRAIN BARRIER; BODY FLUID; CEREBROSPINAL FLUID ANALYSIS; DRUG DEVELOPMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL STUDY; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOMICS; NEUROSCIENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRACTICE GUIDELINE; PROGNOSIS; PROTEIN MICROARRAY; PROTEIN PROCESSING; PROTEOMICS; REVIEW; VALIDATION STUDY;

BIOLOGICAL MARKERS; CEREBROSPINAL FLUID PROTEINS; CHROMATOGRAPHY, LIQUID; DRUG DISCOVERY; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; IMMUNOASSAY; MASS SPECTROMETRY; NERVOUS SYSTEM DISEASES; PEPTIDE FRAGMENTS; PROTEIN ARRAY ANALYSIS; PROTEOME; PROTEOMICS;

EID: 84859388342     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.12.6     Document Type: Review

References (110)

1. Carney RM, Freedland KE. Depression in patients with coronary heart disease. Am. J. Med. 121(11 Suppl. 2), S20-S27 (2008).
2. Frisardi V, Panza F, Farooqui AA. Late-life depression and Alzheimer's disease: the glutamatergic system inside of this mirror relationship. Brain Res. Rev. 67, 344-355 (2011). Elegant translational study providing indications for a relationship between an impaired mechanistic pathway, depression symptoms and Alzheimer's disease.
3. Machado-Vieira R, Zarate CA Jr. Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. Depress. Anxiety 28(4), 267-281 (2011).
4. Dumitriu A, Popescu BO. Placebo effects in neurological diseases. J. Med. Life 3(2), 114-121 (2010).
5. van Gool AJ, Henry B, Sprengers ED. From biomarker strategies to biomarker activities and back. Drug Discov. Today 15(3-4), 121-126 (2010).
6. Hargreaves RJ. The role of molecular imaging in drug discovery and development. Clin. Pharmacol. Ther. 83(2), 349-353 (2008).
7. de Lange EC, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin. Pharmacokinet. 41(10), 691-703 (2002).
8. Bieck PR, Potter WZ. Biomarkers in psychotropic drug development: integration of data across multiple domains. Annu. Rev. Pharmacol. Toxicol. 45, 227-246 (2005).
9. Blennow K, Zetterberg H. Cerebrospinal fluid biomarkers for Alzheimer's disease. J. Alzheimers Dis. 18(2), 413-417 (2009).
10. Romeo MJ, Espina V, Lowenthal M et al. CSF proteome: a protein repository for potential biomarker identification. Expert Rev. Proteomics 2(1), 57-70 (2005). Comprehensive review of earlier cerebrospinal fluid biomarker studies in relation to neurological disorders.
11. de Boer AG, Gaillard PJ. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol. 47, 323-355 (2007).
12. Teunissen CE, Petzold A, Bennett JL et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73(22), 1914-1922 (2009).
13. Zetterberg H, Tullhog K, Hansson O et al. Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients. Eur. Neurol. 63(6), 326-330 (2010).
14. Dekker LJ, Burgers PC, Kros JM, Smitt PA, Luider TM. Peptide profiling of cerebrospinal fluid by mass spectrometry. Expert Rev. Proteomics 3(3), 297-309 (2006).
15. Cook JJ, Wildsmith KR, Gilberto DB et al. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J. Neurosci. 30(19), 6743-6750 (2010).
16. Gilberto DB, Zeoli AH, Szczerba PJ et al. An alternative method of chronic cerebrospinal fluid collection via the cisterna magna in conscious rhesus monkeys. Contemp. Top. Lab. Anim. Sci. 42(4), 53-59 (2003).
17. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics 1(11), 845-867 (2002).
18. Pan S, Zhu D, Quinn JF et al. A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics 7(3), 469-473 (2007).
19. de Lange EC. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv. Drug Deliv. Rev. 56(12), 1793-1809 (2004).
20. Zougman A, Pilch B, Podtelejnikov A et al. Integrated analysis of the cerebrospinal fluid peptidome and proteome. J. Proteome Res. 7(1), 386-399 (2008).
21. Petrak J, Ivanek R, Toman O et al. Déjà vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 8(9), 1744-1749 (2008).
22. Wang P, Bouwman FG, Mariman EC. Generally detected proteins in comparative proteomics - a matter of cellular stress response? Proteomics 9(11), 2955-2966 (2009).
23. Paweletz CP, Wiener MC, Bondarenko AY et al. Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometry. J. Proteome Res. 9(3), 1392-1401 (2010). Good example of a discovery proteomics experiment measuring the technical platform variability and biological variability within the experimental model system, and employing a longitudinal experimental design to identify a candidate mechanism-based pharmacodynamic biomarker in cerebrospinal fluid.
24. Mischak H, Allmaier G, Apweiler R et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci. Transl. Med. 2(46), 46ps42 (2010). Important paper describing the shared opinion of a wide group of experienced clinical biomarker scientists regarding how to properly discover and validate proteomic biomarkers for clinical application.
25. Hale JE, Gelfanova V, You JS, Knierman MD, Dean RA. Proteomics of cerebrospinal fluid: methods for sample processing. Methods Mol. Biol. 425, 53-66 (2008).
26. Jerrard DA, Hanna JR, Schindelheim GL. Cerebrospinal fluid. J. Emerg. Med. 21(2), 171-178 (2001).
27. Rosenling T, Slim CL, Christin C et al. The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF). J. Proteome Res. 8(12), 5511-5522 (2009).
28. Stoop MP, Coulier L, Rosenling T et al. Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples. Mol. Cell Proteomics 9(9), 2063-2075 (2010).
29. Deisenhammer F, Bartos A, Egg R et al. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS Task Force. Eur. J. Neurol. 13(9), 913-922 (2006).
30. Fratantoni SA, Piersma SR, Jimenez CR. Comparison of the performance of two affinity depletion spin filters for quantitative proteomics of CSF: evaluation of sensitivity and reproducibility of CSF analysis using GeLC-MS/MS and spectral counting. Proteomics Clin. Appl. 4(6-7), 613-617 (2010).
31. Mouton-Barbosa E, Roux-Dalvai F, Bouyssié D et al. In-depth exploration of cerebrospinal fluid by combining peptide ligand library treatment and label-free protein quantification. Mol. Cell Proteomics 9(5), 1006-1021 (2010).
32. Millioni R, Tolin S, Puricelli L et al. High abundance proteins depletion vs low abundance proteins enrichment: comparison of methods to reduce the plasma proteome complexity. PLoS One 6(5), e19603 (2011).
33. Mallick P, Kuster B. Proteomics: a pragmatic perspective. Nat. Biotechnol. 28(7), 695-709 (2010).
34. Hanash S. Disease proteomics. Nature 422(6928), 226-232 (2003).
35. Gstaiger M, Aebersold R. Applying mass spectrometry-based proteomics to genetics, genomics and network biology. Nat. Rev. Genet. 10(9), 617-627 (2009).
36. Tumani H, Lehmensiek V, Lehnert S et al. 2D DIGE of the cerebrospinal fluid proteome in neurological diseases. Expert Rev. Proteomics 7(1), 29-38 (2010).
37. Weiss W, Weiland F, Gorg A. Protein detection and quantitation technologies for gel-based proteome analysis. Methods Mol. Biol. 564, 59-82 (2009).
38. Hammack BN, Owens GP, Burgoon MP, Gilden DH. Improved resolution of human cerebrospinal fluid proteins on two-dimensional gels. Mult. Scler. 9(5), 472-475 (2003).
39. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572-577 (2002).
40. Rüetschi U, Zetterberg H, Podust VN et al. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp. Neurol. 196(2), 273-281 (2005).
41. Qin W, Ho L, Wang J, Peskind E, Pasinetti GM. S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. PLoS One 4(1), e4183 (2009).
42. Ekblad L, Baldetorp B, Ferno M, Olsson H, Bratt C. In-source decay causes artifacts in SELDI-TOF MS spectra. J.Res. 6(4), 1609-1614 (2007).
43. Whelan LC, Power KA, McDowell DT, Kennedy J, Gallagher WM. Applications of SELDI-MS technology in oncology. J. Cell Mol. Med. 12(5A), 1535-1547 (2008).
44. Kaufmann R. Matrix-assisted laser desorption ionization (MALDI) mass spectrometry: a novel analytical tool in molecular biology and biotechnology. J. Biotechnol. 41(2-3), 155-175 (1995).
45. van Kampen JJ, Burgers PC, de Groot R et al. Quantitative analysis of HIV-1 protease inhibitors in cell lysates using MALDI-FTICR mass spectrometry. Anal. Chem. 80(10), 3751-3756 (2008).
46. Stoop MP, Dekker LJ, Titulaer MK et al. Quantitative matrix-assisted laser desorption ionization-Fourier transform ion cyclotron resonance (MALDI-FT-ICR) peptide profiling and identification of multiple-sclerosis- related proteins. J. Proteome Res. 8(3), 1404-1414 (2009).
47. Magparangalan DP, Garrett TJ, Drexler DM, Yost RA. Analysis of large peptides by MALDI using a linear quadrupole ion trap with mass range extension. Anal. Chem. 82(3), 930-934 (2010).
48. Hanrieder J, Wetterhall M, Enblad P, Hillered L, Bergquist J. Temporally resolved differential proteomic analysis of human ventricular CSF for monitoring traumatic brain injury biomarker candidates. J. Neurosci. Methods 177(2), 469-478 (2009).
49. Portelius E, Tran AJ, Andreasson U et al. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J. Proteome Res. 6(11), 4433-4439 (2007).
50. Mann M, Kelleher NL. Precision proteomics: the case for high resolution and high mass accuracy. Proc. Natl Acad. Sci. USA 105(47), 18132-18138 (2008).
51. Tran JC, Zamdborg L, Ahlf DR et al. Mapping intact protein isoforms in discovery mode using top-down proteomics. Nature 480, 254-258 (2011).
52. Mazur MT, Cardasis HL, Spellman DS, Liaw A, Yates NA, Hendrickson RC. Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry. Proc. Natl Acad. Sci. USA 107(17), 7728-7733 (2010).
53. Wang W, Zhou H, Lin H et al. Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. Anal. Chem. 75(18), 4818-4826 (2003).
54. Wiener MC, Sachs JR, Deyanova EG, Yates NA. Differential mass spectrometry: a label-free LC-MS method for finding significant differences in complex peptide and protein mixtures. Anal. Chem. 76(20), 6085-6096 (2004).
55. Meng F, Wiener MC, Sachs JR et al. Quantitative analysis of complex peptide mixtures using FTMS and differential mass spectrometry. J. Am. Soc. Mass Spectrom. 18(2), 226-233 (2007).
56. Gilmore JM, Washburn MP. Advances in shotgun proteomics and the analysis of membrane proteomes. J. Proteomics 73(11), 2078-2091 (2010).
57. Wu CC, MacCoss MJ. Shotgun proteomics: tools for the analysis of complex biological systems. Curr. Opin. Mol. Ther. 4(3), 242-250 (2002).
58. Gao J, Friedrichs MS, Dongre AR, Opiteck GJ. Guidelines for the routine application of the peptide hits technique. J. Am. Soc. Mass Spectrom. 16(8), 1231-1238 (2005).
59. Liu H, Sadygov RG, Yates JR 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 76(14), 4193-4201 (2004).
60. Zhang J, Goodlett DR, Peskind ER et al. Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol. Aging 26(2), 207-227 (2005).
61. Li M, Gray W, Zhang H et al. Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling. J. Proteome Res. 9(8), 4295-4305 (2010).
62. Michalski A, Cox J, Mann M. More than 100,000 detectable peptide species elute in single shotgun proteomics runs but the majority is inaccessible to data-dependent LC-MS/MS. J. Proteome Res. 10(4), 1785-1793 (2011).
63. Ong SE, Foster LJ, Mann M. Mass spectrometric-based approaches in quantitative proteomics. Methods 29(2), 124-130 (2003).
64. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17(10), 994-999 (1999).
65. Hsu JL, Huang SY, Chow NH, Chen SH. Stable-isotope dimethyl labeling for quantitative proteomics. Anal. Chem. 75(24), 6843-6852 (2003).
66. Ishihama Y, Sato T, Tabata T et al. Quantitative mouse brain proteomics using culture-derived isotope tags as internal standards. Nat. Biotechnol. 23(5), 617-621 (2005).
67. Liao L, Sando RC, Farnum JB, Vanderklish PW, Maximov A, Yates JR. (15)N-labeled brain enables quantification of proteome and phosphoproteome in cultured primary neurons. J. Proteome Res. 11(2), 1341-1353 (2011).
68. Krüger M, Moser M, Ussar S et al. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 134(2), 353-364 (2008).
69. Bateman RJ, Munsell LY, Chen X et al. Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J. Am. Soc. Mass Spectrom. 18(6), 997-1006 (2007).
70. Zhang J, Goodlett DR, Quinn JF et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimers Dis. 7(2), 125-133 (2005).
71. Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell Proteomics 3(12), 1154-1169 (2004).
72. Thompson A, Schafer J, Kuhn K et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem. 75(8), 1895-1904 (2003).
73. Abdi F, Quinn JF, Jankovic J et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis. 9(3), 293-348 (2006).
74. Dayon L, Turck N, Scherl A, Hochstrasser DF, Burkhard PR, Sanchez JC. From relative to absolute quantification of tryptic peptides with tandem mass tags: application to cerebrospinal fluid. Chimia 64(3), 132-135 (2010).
75. Ow SY, Salim M, Noirel J et al. iTRAQ underestimation in simple and complex mixtures: 'the good, the bad and the ugly'. J. Proteome Res. 8(11), 5347-5355 (2009).
76. Karp NA, Huber W, Sadowski PG, Charles PD, Hester SV, Lilley KS. Addressing accuracy and precision issues in iTRAQ quantitation. Mol. Cell. Proteomics 9(9), 1885-1897 (2010).
77. Careri M, Mangia A. Validation and qualification: the fitness for purpose of mass spectrometry-based analytical methods and analytical systems. Anal. Bioanal. Chem. 386(1), 38-45 (2006).
78. van Weemen BK, Schuurs AH. Immunoassay using antigen-enzyme conjugates. FEBS Lett. 15(3), 232-236 (1971).
79. Fulton RJ, McDade RL, Smith PL, Kienker LJ, Kettman JR Jr. Advanced multiplexed analysis with the FlowMetrix system. Clin. Chem. 43(9), 1749-1756 (1997).
80. Mattsson N, Axelsson M, Haghighi S et al. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Mult. Scler. 15(4), 448-454 (2009).
81. Hartmann M, Roeraade J, Stoll D, Templin MF, Joos TO. Protein microarrays for diagnostic assays. Anal. Bioanal. Chem. 393(5), 1407-1416 (2009).
82. Niemeyer CM, Adler M, Wacker R. Detecting antigens by quantitative immuno-PCR. Nat. Protoc. 2(8), 1918-1930 (2007).
83. Fasolo J, Snyder M. Protein microarrays. Methods Mol. Biol. 548, 209-222 (2009).
84. Paweletz CP, Charboneau L, Bichsel VE et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20(16), 1981-1989 (2001).
85. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell Proteomics 5(4), 573-588 (2006). Landmark paper outlining the practical aspects of developing multiple reaction monitoring-based targeted mass spectrometry biomarker assays.
86. Gallien S, Duriez E, Domon B. Selected reaction monitoring applied to proteomics. J. Mass Spectrom. 46(3), 298-312 (2011). Recent update of the status and opportunities of targeted proteomics by selected reaction monitoring mass spectrometry.
87. Pratt JM, Simpson DM, Doherty MK, Rivers J, Gaskell SJ, Beynon RJ. Multiplexed absolute quantification for proteomics using concatenated signature peptides encoded by QconCAT genes. Nat. Protoc. 1(2), 1029-1043 (2006).
88. Addona TA, Abbatiello SE, Schilling B et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 27(7), 633-641 (2009). Elegantly describes a multicenter analysis of the robustness of multiple reaction monitoring mass spectrometry assays using shared samples and standardized protocols.
89. Bystrom CE, Salameh W, Reitz R, Clarke NJ. Plasma renin activity by LC-MS/MS: development of a prototypical clinical assay reveals a subpopulation of human plasma samples with substantial peptidase activity. Clin. Chem. 56(10), 1561-1569 (2010).
90. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J. Proteome Res. 3(2), 235-244 (2004).
91. Sparbier K, Wenzel T, Dihazi H et al. Immuno-MALDI-TOF MS: new perspectives for clinical applications of mass spectrometry. Proteomics 9(6), 1442-1450 (2009).
92. Bateman RJ, Munsell LY, Morris JC et al. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12(7), 856-861 (2006).
93. Mawuenyega KG, Sigurdson W, Ovod V et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330(6012), 1774 (2010).
94. Jovanovic M, Reiter L, Picotti P et al. A quantitative targeted proteomics approach to validate predicted microRNA targets in C. elegans. Nat. Methods 7(10), 837-842 (2010).
95. Thomas A, Lenglet S, Chaurand P et al. Mass spectrometry for the evaluation of cardiovascular diseases based on proteomics and lipidomics. Thromb. Haemost. 106(1), 20-33 (2011).
96. Gieger C, Geistlinger L, Altmaier E et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet. 4(11), e1000282 (2008).
97. Martin JN, Bair TB, Bode N, Dauer WT, Gonzalez-Alegre P. Transcriptional and proteomic profiling in a cellular model of DYT1 dystonia. Neuroscience 164(2), 563-572 (2009).
98. Ideker T, Thorsson V, Ranish JA et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292(5518), 929-934 (2001).
99. Ideker T, Dutkowski J, Hood L. Boosting signal-to-noise in complex biology: prior knowledge is power. Cell 144(6), 860-863 (2011).
100. Wishart DS, Lewis MJ, Morrissey JA et al. The human cerebrospinal fluid metabolome. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 871(2), 164-173 (2008).
101. Yan G, Zhang G, Fang X et al. Genome sequencing and comparison of two nonhuman primate animal models, the cynomolgus and Chinese rhesus macaques. Nat. Biotechnol. 29(11), 1019-1023 (2011).
102. Mueller SG, Weiner MW, Thal LJ et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 1(1), 55-66 (2005).
103. Kellner R, Voshol H, Cutler P, Leonardsen Ronnedal L, Verhaert P. European Pharmaceutical Proteomics Laboratories: proteomics in the pharma industry in Europe. Proteomics 3, 108 (2003).
104. Lamers KJ, Vos P, Verbeek MM et al. Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res. Bull. 61(3), 261-264 (2003).
105. Boston PF, Jackson P, Thompson RJ. Human 14-13-3 protein: radioimmunoassay, tissue distribution, and cerebrospinal fluid levels in patients with neurological disorders. J. Neurochem. 38(5), 1475-1482 (1982).
106. Mattsson N, Andreasson U, Persson S et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 7(4), 386-395 (2011).
107. Rupprecht TA, Pfister HW, Angele B et al. The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis. Neurology 65(3), 448-450 (2005).
108. Schmidt C, Plate A, Angele B et al. A prospective study on the role of CXCL13 in Lyme neuroborreliosis. Neurology 76(12), 1051-1058 (2011).
109. Molecular & Cellular Proteomics. Publication guidelines for the analysis and documentation of peptide and protein identifications. www.mcponline.org/site/misc/ParisReport-Final.xhtml
110. US Department of Health and Human Services, Food and Drug Administration. Guidance for industry: bioanalytical method validation (2001).www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf